Tornier Toes FTC Line With Lower-Extremity Sale To Integra
This article was originally published in The Gray Sheet
Executive Summary
Integra is buying the U.S. rights to Tornier's Salto Talaris and Salto XT ankle replacement products and its Futura silastic toe replacement products for an undisclosed cash payment. The deal is intended to satisfy antitrust concerns in Wright Medical's pending purchase of Tornier and to strengthen Integra's position in the lower-extremity market.
You may also be interested in...
Device Debuts: Tryton, Myriad Genetics, Integra Lifesciences, Acelity, And Toyota
This edition of device debuts highlights a wide variety of innovative devices introduced into commercial markets since the beginning of March, including a new stent for side-branch coronary interventions, an assay that identifies which breast-cancer patients do not need chemotherapy, a full ankle prosthesis, improvements to a negative-pressure wound therapy system, and a robotic system that helps paralyzed people learn to walk again.
Wright Moves More To Extremes With Tornier Purchase Agreement
The all-stock transaction valued at around $3.3 billion will create a device and biologics company with a comprehensive focus on orthopedic extremities surgery. The firms expect cost synergies of $40 to $45 million.